Sector Update: Health Care Stocks Gain in Afternoon Trading
Health care stocks rose Tuesday afternoon with the NYSE Health Care Index gaining 0.9% and the Health Care Select Sector SPDR Fund (XLV) up 1.1%.The iShares Biotechnology ETF (IBB) climbed 1.7%.In
Nkarta Shares Rise After Co. Names President and Chief Medical Officer
By Stephen Nakrosis Shares of Nkarta were trading in the green Tuesday, after the biopharmaceutical company said a former executive will be returning in the newly-created role of president. The
Express News | Nkarta Shares Are Trading Higher After the Company Appointed Nadir Mahmood as President
Express News | Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President
Nkarta (NKTX) Upgraded to Buy: Here's What You Should Know
We Think Nkarta (NASDAQ:NKTX) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Nkarta (NASDAQ:NKTX) has seen its share price rise 141% over the last year, delighting many sh
Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $18
Stifel analyst Stephen Willey maintains $Nkarta(NKTX.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 40.8% and a total avera
Express News | Needham Reiterates Buy on Nkarta, Maintains $13 Price Target
William Blair Maintains Nkarta(NKTX.US) With Buy Rating
William Blair analyst Sami Corwin maintains $Nkarta(NKTX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 35.3% and a total average return of -4.8% over the past ye
Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $13
Needham analyst Gil Blum maintains $Nkarta(NKTX.US)$ with a buy rating, and maintains the target price at $13.According to TipRanks data, the analyst has a success rate of 38.6% and a total average re
H.C. Wainwright Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $23
H.C. Wainwright analyst Emily Bodnar maintains $Nkarta(NKTX.US)$ with a buy rating, and maintains the target price at $23.According to TipRanks data, the analyst has a success rate of 31.6% and a tota
Express News | Nkarta Initiates Ntrust-1 Of NKX019 In Lupus Nephritis, With First Patient In Screening. FDA Also Clears Second Investigational New Drug Application For NKX019 In Autoimmune Disease
Express News | Nkarta Inc: Clinical Data From Ntrust-1 and Ntrust-2 Planned for 2025
Express News | Nkarta Initiates Clinical Trial of Nkx019 in Lupus Nephritis With First Patient in Screening and Announces Pipeline Expansion to Additional Autoimmune Indications
Express News | Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.d., Facr, to Board of Directors
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
EnGene Holdings: Nkarta's Paul Hastings and Forbion's Wouter Joustra Elected to Bd >ENGN
EnGene Holdings: Nkarta's Paul Hastings and Forbion's Wouter Joustra Elected to Bd >ENGN
Nkarta Price Target Raised to $23.00/Share From $22.00 by HC Wainwright & Co.
Nkarta Price Target Raised to $23.00/Share From $22.00 by HC Wainwright & Co.
Nkarta Is Maintained at Buy by Needham
Nkarta Is Maintained at Buy by Needham
Express News | Needham Maintains Buy on Nkarta, Lowers Price Target to $13